Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. September 2020 08:00 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotech to Present at HC Wainwright and Morgan Stanley Healthcare Conferences

PITTSBURGH, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus...
25. August 2020 08:00 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotech Announces Initiation of Phase 1 Study Evaluating KB301 in Aesthetic Indications

KB103 is designed to deliver a full-length human type III collagen transgene via intradermal injection First in-human study will evaluate the safety and efficacy in acne scars and facial...
17. August 2020 16:01 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotech’s KB407 Granted Orphan Drug Designation by the FDA to Treat Patients With Cystic Fibrosis

PITTSBURGH, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector...
10. August 2020 08:00 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotech Reports Second Quarter 2020 Financial Results and Provides Update on Operational Progress

Initiated the pivotal GEM-3 clinical study evaluating B-VEC in DEB patients Today announced enrollment of 1st patient in Phase 2 clinical study evaluating KB105 in ARCI patients On track to...
30. Juli 2020 08:00 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotech to Present at the William Blair BioTech Conference

PITTSBURGH, July 30, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus...
28. Juli 2020 16:44 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotech Announces Initiation of Pivotal Phase 3 Study of Beremagene Geperpavec in Patients with Dystrophic Epidermolysis Bullosa

The randomized, double-blind GEM-3 trial will compare repeat dosing of either B-VEC or placebo in approximately 30 dystrophic epidermolysis bullosa (DEB) patients Top line data and BLA filing are...
20. Juli 2020 08:00 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotech Appoints Whitney Ijem as Senior Vice President, Strategy and Business Development

PITTSBURGH, July 20, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector...
08. Juni 2020 16:01 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotech to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast

PITTSBURGH, June 08, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing transformative medicines to treat diseases caused by...
18. Mai 2020 21:57 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotech Announces Pricing of $125 Million Public Offering of Common Stock

PITTSBURGH, May 18, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company developing a new class of transformative medicines to treat diseases caused...
18. Mai 2020 16:15 ET | Quelle: Krystal Biotech, Inc.

Krystal Biotech Announces Proposed Public Offering of Common Stock

PITTSBURGH, May 18, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company developing a new class of transformative medicines to treat diseases caused...

Vorherige Seite